The vast majority of follicular lymphomas (FL) originate in lymph nodes and are characterized by a specific oncogenic event, the t(14;18)(q32;q21) translocation, juxtaposing the BCL2 gene on chromosome 18 with the immunoglobulin heavy chain locus on chromosome 14, leading to the overexpression of the antiapoptotic molecule BCL2. 1 On the other hand, there is a group of t(14;18)(q32;q21)-negative FLs, mostly found in skin or in other extranodal sites as well as in lymph nodes. 2 Follicular center cell lymphomas of the spleen rarely arise as primary splenic follicular lymphoma (PSFL), but involvement of the spleen is common in the context of a generalized lymphoma. To date, there are no data about the biological features of PSFL, due to the sporadic frequency of this pathologic entity. We report a PSFL case showing a novel fusion gene involving P2RY8 (G-protein coupled purinergic receptor P2Y8), and SOX5, one of the Sry (sex-determining region Y)-box (SOX) genes. The fusion was detected by fluorescence in situ hybridization (FISH) and reverse transcription (RT)-PCR. The P2RY8/SOX5 chimera resulted in the overexpression of SOX5 and the encoded protein, evaluated by real-time quantitative PCR (RQ-PCR) and immunohistochemistry, respectively.
In January 2004, a 58-year-old male patient presented with leukopenia (WBC count 3 Â 10 9 /l) and thrombocytopenia (PLT count 65 Â 10 9 /l). Physical examination showed splenomegaly (3 cm below the costal margin). Peripheral blood, bone marrow trephine and aspirate analysis did not reveal hematological disorders. Moreover, immunophenotypic and conventional cytogenetic analysis did not show clonal diseases. Virological search and total body computed tomography (CT) scans were negative. During the follow-up, the biological and clinical Dual-color FISH using RP11-83J21 (labeled in spectrum orange) and RP11-232M22 (labeled in spectrum green) showing two fusion genes. FISH, fluorescence in situ hybridization.
features of the patient were stable with the exception of the slowly increasing spleen volume. In February 2006, the patient presented burden splenic symptoms. He was therefore treated with splenectomy (spleen maximum diameter was 26 cm, weight 1.7 kg). Spleen histological examination (Figures 1a  and b ) revealed a grade I FL according to the WHO classification. The neoplastic component coexpressed CD20, CD10 ( Figure 1c ) and BCL6 (Figure 1d ) with monotypic light chain restriction; CD5, CD21, CCND1 and BCL2 were negative. The pattern of growth was almost exclusively nodular. FISH and RT-PCR analyses excluded the occurrence of both IGH/BCL2 and IGH/CCND1 fusion genes (data not shown). Moreover, appropriate FISH experiments showed neither IGH/BCL3 nor IGH/BCL6 cryptic fusion genes (data not shown). Total body CT scans, bone marrow trephine and aspirate examination were negative. In accordance with these data, the diagnosis of PSFL was made.
Chromosome analysis, performed on direct preparation of spleen cells, revealed the karyotype 46,XY,t(X;12)(p22;p12) (Table 1) yielded a single band of 235 and 718 bp, respectively ( Figure 2c ). The sequencing of these two bands revealed the occurrence of a P2RY8/SOX5 fusion transcript ( Figure 2e ). Interestingly, the primer combination P2RY8ex1-23F/SOX5ex6-95R produced three main fragments of 831, 756 and 651 bp, in addition to two fainter bands ( Figure 2d ). The three main bands were sequenced for further characterization of the fusion breakpoint. In all the three transcripts, nt 187 of exon 1 of P2RY8 (accession no. NM_178129) was fused with nt 117 of exon 2 of SOX5 (mRNA with accession number BC060773) (Figures 2d and e) . However, a precise determination of the fusion point was not possible due to the existence of an identical AG dinucleotide at the junction (position 186-187 in P2RY8 and 117-118 in SOX5 cDNA). In both transcripts of types 2 and 3, part of exon 6 (105 bp, position 577-681 in BC060773, downstream to the ATG starting codon 3 ) was alternatively spliced out (Figures 2d and e) , as well as the whole exon 5 3) and of a normal control (lanes 2 and 4), using primer sets (a) (P2RY8ex1-23F/SOX5ex2-70R, lanes 1 and 2) and (b) (P2RY8-23F/SOX5ex6-222R, lanes 3 and 4). Chimeric transcripts of 235 and 718 bp are evident in lanes 1 and 3, respectively. (d) Analysis of the P2RY8/SOX5 fusion transcripts. M: 2-log DNA Ladder (New England Biolabs, Milan, Italy). Lane 1: three fusion transcripts were detected using P2RY8-23F þ SOX5ex6-95R in the patient's cDNA. Lane 2: no fusion transcript was detected in a normal peripheral blood sample. Lane 3: blank. (e) Complete nucleotide sequence of P2RY8/SOX5 chimeric transcript 1. The sequence of all the primers used in PCR experiments are underlined (the two halves of SOX5ex6-119F are in purple). The arrowhead indicates the P2RY8/SOX5 transcript junction, and vertical lines indicate exon boundaries. The alternatively spliced exon 5 (n) in transcript 3 is represented in italics. SOX5 exon 6 sequence in bold is absent in type 2 and 3 chimeric transcript. (f) Expression analysis of SOX5 evaluated by RQ-PCR, showing a higher SOX5 transcriptional level in the patient with t(X;12) versus three normal spleen (S1-3) and three nodal FL control samples (NFL1-3) ; the mean C t value of the spleen controls (mean value (S1-3)); and the mean C t value of the nodal FL controls (mean value (NFL1-3) ). FISH, fluorescence in situ hybridization.
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(present as a cryptic exon in mRNA BC066773, position 375-449, but not in the RefSeq transcript NM_152989) in the type 3 transcript (Figures 2d and e) .
None of the three amplified transcripts resulted in a chimeric in-frame P2RY8/SOX5. The fusion breakpoint, in all the three fusion transcripts, mapped before the start of the P2RY8 coding sequence (P2RY8 exon 2) and preserved the SOX5 ATG initiation codon, which begins at the second nucleotide of SOX5 exon 6 (BC060773) (Figure 2e ). RT-PCR for the reciprocal SOX5/P2RY8 fusion product, using SOX5 exon 1 forward and P2RY8 exon 2 reverse primers, yielded negative results (data not shown). The expression level of SOX5 was determined by RQ-PCR using 1X PlatinumSYBR Green qPCR SuperMix-UDG (Invitrogen, Carlsbad, CA, USA). Proper primer combinations were used to discriminate among splicing variants. In detail, the SOX5ex6-162F/SOX5ex7-42R allowed the amplification of transcript variant type I only. The other two variants (types 2 and 3) were obtained using SOX5ex6-119F/SOX5ex7-42R (Figures 2d-f) . 28S rRNA was used as reference gene and one (no. 3, Figure 2f ) of the three normal spleen samples was utilized as calibrator. The gene expression level variation was estimated by comparing the values of 2
ÀDDCt (relative amount of cDNA) for the SOX5 C t values in the patient with t(X;12), three cases of nodal FL, and three normal spleen samples, with the relative value of the calibrator. Moreover, the C t mean values of the three normal spleen samples and the three FL patients were also considered during the analysis. The significance was estimated by comparing the respective ranges ( 2 ÀDDCt 7s.d.) of these values (Figure 2f ). This analysis revealed a clear upregulation of all the SOX5 splicing variants in the case with the t(X;12) rearrangement (Figure 2f ). Immunohistochemical analysis using two different SOX5 antibodies, based on a guinea pig antibody 4 and a rabbit anti-SOX5 antibody (Abcam ab26041), showed nuclear overexpression of the SOX5 protein in most of the neoplastic follicular cells (Figure 1e ). SOX5 immunoreactivity was absent in five cases of t(14;18) positive FL (data not shown).
In the present study, we demonstrated the overexpression of SOX5 in a case of PSFL with a t(X;12)(p22;p12) (Figure 2f ). The mechanism responsible for the transcriptional deregulation of an oncogene through its juxtaposition to an ectopic promoter is known as 'promoter swapping'. 5 It has been reported in several tumors (pleomorphic adenoma of the salivary glands, lipoblastoma, aneurysmal bone cyst, teratoma). Since the SOX5 (BC066773) open reading frame was preserved, its upregulation should be just the consequence of the juxtaposition to the P2RY8 promoter sequence. Thus it can be considered a further example of a promoter swapping.
P2RY8 has not been directly implicated in tumorigenesis. Apart from the t(X;12) rearrangement described in the present study, this gene has been reported to be disrupted in a pericentric inversion of the X chromosome [inv(X)(p22.3;q13.2)] in a family with two mentally retarded males. 6 Database and a literature report 6 clearly show a high expression level of the P2RY8 gene in lymphocytes and in lymph. Consequently, its promoter can be supposed to be potentially able to activate SOX5. The SOX5 gene encodes a member of the SOX family of transcription factors, which are recognized as key players in the regulation of embryonic development and in the determination of the cell fate. SOX5 is known to express two types of alternatively spliced transcripts, short (existing only in the testis) and long forms (L-SOX5), expressed in multiple tissues and showing several isoforms. 3 The L-SOX5 protein may play an important role in chondrogenesis 3 and in oligodendrocyte development. 4 There is limited knowledge about a possible role of L-SOX5 in other tissues and in human cancer. SOX5 was recently shown to be aberrantly overexpressed in glioma, and recognized as a glioma antigen using IgGs from the sera of glioma patients.
7 SOX5 was also reported to be amplified, along with DADR and ETNK1, in testicular seminomas, although no SOX5 overexpression was detected. 8 In conclusion, the PSFL case we have studied presents evidence, for the first time, of the overexpression of SOX5 consequent to a promoter swapping event juxtaposing its coding sequence to the P2RY8 promoter. Further studies are needed to clarify the possible role of aberrant SOX5 gene expression in the pathogenesis of PSFL and of other t(14;18) negative FL. P2RY8ex1-23F  CACGAACACCTTCTCAAGCA  NM_178129  23-42  P2RY8ex1-162F  CTACTTCTGCCGCTGCTTCT  NM_178129  162-181  P2RY8ex2-265R  AGATTTGGAAAGGCAACACG  NM_178129  433-452  P2RY8x2-901R  AAACAAACGGGTCCAGACAG  NM_178129  1069-1088  SOX5ex1-16F  CACCAAAACCCATCTCCAGT  BC060773  20-39  SOX5ex1-94F  GCATTAACGAGACCGGGTAA  BC060773  98-117  SOX5ex2-70R  GGGAGGCTTGTCCAAAACTT  BC060773  169-188  SOX5ex6-56R  TGGCTACCTCTCCATCTGCT  BC060773  486-505  SOX5ex6-222R  TGCTGAGAAGTGGGAGTCCT  BC060773  652- Letters to the Editor
